Home › Funds › MPM BioImpact LLC › DNTH
MPM BioImpact LLC position in DNTH
DIANTHUS THERAPEUTICS INC · Health Care
MPM BioImpact LLC reported holding 420,002 shares of DNTH (DIANTHUS THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$40.9M, representing 2.50% of its reported portfolio and ranking #16 among its reported holdings. MPM BioImpact LLC has disclosed DNTH holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MPM BioImpact LLC's DNTH position evolved
MPM BioImpact LLC first disclosed a stake in DNTH in Q1 2026 at 423,982 shares (US$35.6M). The position peaked in Q2 2026 at 420,002 shares, worth US$40.9M. Across 2 filings, MPM BioImpact LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 420,002 shares valued at US$40.9M — a reduction of -3,980 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 423.98K | $35.58M | New |
| Q2 2026 | 420.00K | $40.94M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DNTH and 13F data
DNTH (DIANTHUS THERAPEUTICS INC) is a Health Care company. 72 other funds we track also report a position in DNTH — the largest reported positions include Fairmount Funds Management LLC (US$247.3M), Avidity Partners Management LP (US$205.1M), Octagon Capital Advisors LP (US$179.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DNTH
- Fairmount Funds Management LLC 2.54M sh · $247.33M · Q2 2026
- Avidity Partners Management LP 2.10M sh · $205.12M · Q2 2026
- Octagon Capital Advisors LP 1.84M sh · $179.53M · Q2 2026
- TCG Crossover Management, LLC 1.68M sh · $163.44M · Q2 2026
- FRED ALGER MANAGEMENT, LLC 1.30M sh · $126.97M · Q2 2026
- Venrock Adviser, LLC 1.18M sh · $115.03M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.13M sh · $109.70M · Q2 2026
- BAKER BROS. ADVISORS LP 852.16K sh · $83.07M · Q2 2026
- Logos Global Management LP 800.00K sh · $77.98M · Q2 2026
- Cormorant Asset Management, LP 750.00K sh · $73.11M · Q2 2026
- BRAIDWELL LP 594.56K sh · $57.96M · Q2 2026
- Affinity Asset Advisors, LLC 400.00K sh · $38.99M · Q2 2026
More on MPM BioImpact LLC
FAQ
How long has MPM BioImpact LLC held DNTH?
MPM BioImpact LLC has disclosed DNTH holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is MPM BioImpact LLC's current position in DNTH?
As of Q2 2026, MPM BioImpact LLC holds 420.00K shares of DNTH (DIANTHUS THERAPEUTICS INC), valued at $40.94M, representing 2.50% of its reported portfolio and ranking #16.
Has MPM BioImpact LLC been buying or selling DNTH?
In the latest 13F filing (Q2 2026), MPM BioImpact LLC reduced its position in DNTH. The position peaked in Q2 2026 at 420.00K shares.
Which other funds hold DNTH?
Other major institutional holders of DNTH include Fairmount Funds Management LLC, Avidity Partners Management LP, Octagon Capital Advisors LP, among 72 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.